Open competition
Open procedure: the contract was advertised and any supplier could submit a bid.
Key facts
- Buyer
- NHS England · Body governed by public law
- Suppliers
- Biogen, GlaxoSmithKline UK Limited, Samsung Bioepis UK Ltd SME, Pfizer Ltd, Janssen-Cilag Ltd, Celltrion Healthcare United Kingdom Limited, Abbvie Ltd, Takeda UK Ltd, Organon Pharmaceuticals UK Ltd, Alexion Pharmaceuticals SME, Orifarm UK, Amgen Ltd +9 more
- Value
- £24 across 24 lots
- Procedure
- Open procedure
- Sector
- Medical equipment & pharmaceuticals · Pharmaceutical products (CPV 33600000)
- Region
- London
- Official notice
- 043951-2025 on Find a Tender
- Timeline
-
- Contract date1 Jul 2025
- Published29 Jul 2025Published 28 days after the contract date
Description
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Lots in this award
| Lot | Supplier | Value |
|---|---|---|
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Biogen | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | GlaxoSmithKline UK Limited | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Samsung Bioepis UK Ltd SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Pfizer Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Janssen-Cilag Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Celltrion Healthcare United Kingdom Limited | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Abbvie Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Takeda UK Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Organon Pharmaceuticals UK Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Alexion Pharmaceuticals SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Orifarm UK | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Amgen Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | CuraTeQ Biologics s.r.o. SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Dr Reddy's Laboratories (UK) Ltd SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Amgen Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Samsung Bioepis UK Ltd SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Alexion Pharmaceuticals SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Sobi (Swedish Orphan Biovitrum Ltd) SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Zentiva Pharma UK Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Fresenius Kabi Limited | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Sandoz Ltd SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Thornton & Ross SME | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Roche Products Ltd | £1 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | Accord-UK Ltd SME | £1 |
About the suppliers
Biogen: every public contract they have won, plus their Companies House record (company 01497267).
Amgen Ltd: every public contract they have won.
Sobi (Swedish Orphan Biovitrum Ltd): every public contract they have won, plus their Companies House record (company 04369760).
Zentiva Pharma UK Ltd: every public contract they have won, plus their Companies House record (company 02158996).
Fresenius Kabi Limited: every public contract they have won, plus their Companies House record (company 02182135).
Sandoz Ltd: every public contract they have won, plus their Companies House record (company 01547204).
Thornton & Ross: every public contract they have won, plus their Companies House record (company 00185947).
Roche Products Ltd: every public contract they have won, plus their Companies House record (company 04369760).
Accord-UK Ltd: every public contract they have won, plus their Companies House record (company 00079585).
GlaxoSmithKline UK Limited: every public contract they have won, plus their Companies House record (company 04310159).
Samsung Bioepis UK Ltd: every public contract they have won.
Pfizer Ltd: every public contract they have won, plus their Companies House record (company 00526209).
Janssen-Cilag Ltd: every public contract they have won, plus their Companies House record (company 01027904).
Celltrion Healthcare United Kingdom Limited: every public contract they have won, plus their Companies House record (company 11685363).
Abbvie Ltd: every public contract they have won, plus their Companies House record (company 08004972).
Takeda UK Ltd: every public contract they have won, plus their Companies House record (company 03362860).
Organon Pharmaceuticals UK Ltd: every public contract they have won.
Alexion Pharmaceuticals: every public contract they have won.
Orifarm UK: every public contract they have won, plus their Companies House record (company 10015046).
CuraTeQ Biologics s.r.o.: every public contract they have won.
Dr Reddy's Laboratories (UK) Ltd: every public contract they have won, plus their Companies House record (company 01729064).